Shots:

• Merck has agreed to acquire EyeBio for expanding its ophthalmologic portfolio. The transaction is anticipated to conclude in Q3’24
• Merck will acquire all EyeBio’s outstanding shares for an aggregate of $3B, consisting of $1.3B upfront in cash and up to $1.7B in developmental, regulatory & commercial milestones. Merck expects a $1.3B charge (about $0.50 per unit) in non-GAAP results during the closing quarter
• The acquisition adds EyeBio’s Restoret (EYE103), which will progress into a P-IIb/III study in H2’24 based on the data from P-Ib/IIa (AMARONE) trial for diabetic macular edema (DME) & neovascular age-related macular degeneration (NVAMD), as well as a preclinical pipeline focusing on retinal diseases to Merck’s portfolio. EyeBio will continue Restoret’s development through its expertise as a part of Merck

Ref: Merck | Image: Merck

Related News:- Merck Reports the Data from P-III (KEYNOTE-522) Study of Keytruda for Treating Triple Negative Breast Cancer (TNBC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com